21 Result(s)

Article

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are incretin-derived glucose-lowering agents that have been used for the treatment of type 2 diabetes since 2007. Agents such as exenatide (short-acting ...

M. A. Nauck, O. Baranov, R. A. Ritzel, J. J. Meier in Diabetologia (2013)

Article

Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans

Diabetes frequently develops in patients with pancreatic disorders. We aimed to determine the lower threshold of beta cell area for diabetes manifestation as well as the impact of insulin sensitivity on glucos...

J. J. Meier, T. G. K. Breuer, R. C. Bonadonna, A. Tannapfel, W. Uhl… in Diabetologia (2012)

Article

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

The incretin hormones gastric inhibitory polypeptide and especially glucagon-like peptide (GLP) have an important physiological function in augmenting postprandial insulin secretion. Since GLP-1 may play a rol...

M. A. Nauck, I. Vardarli, C. F. Deacon, J. J. Holst, J. J. Meier in Diabetologia (2011)

Article

Determinants of glucose control in patients with chronic pancreatitis

Diabetes frequently develops in patients with chronic pancreatitis (CP). Partial pancreatectomy has emerged as a treatment option for such patients. We addressed whether the development of diabetes in CP patie...

H. Schrader, B. A. Menge, C. Zeidler, P. R. Ritter, A. Tannapfel, W. Uhl… in Diabetologia (2010)

Article

Metabolic consequences of a 50% partial pancreatectomy in humans

Partial pancreatectomy is frequently performed in patients with pancreatic tumours or chronic pancreatitis, but little is known about the metabolic impact of this intervention. We examined the effects of appro...

B. A. Menge, H. Schrader, T. G. K. Breuer, Y. Dabrowski, W. Uhl… in Diabetologia (2009)

Article

Beta cell mass in diabetes: a realistic therapeutic target?

Beta cell deficiency underlies both type 1 and type 2 diabetes, and restoration or replacement of beta cell function is therefore the logical long-term solution to therapy. This review sets out to describe the...

J. J. Meier in Diabetologia (2008)

Article

The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms

M. A. Nauck, J. J. Meier in Diabetologia (2007)

Article

Modestly increased beta cell apoptosis but no increased beta cell replication in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis

Type 1 diabetes is characterised by a deficit in beta cell mass thought to be due to immune-mediated increased beta cell apoptosis. Beta cell turnover has not been examined in the context of new-onset type 1 d...

A. E. Butler, R. Galasso, J. J. Meier, R. Basu, R. A. Rizza, P. C. Butler in Diabetologia (2007)

Article

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

The incretin effect describes the augmentation of postprandial insulin secretion by gut hormones. It is not known whether glucagon secretion is also influenced by an incretin effect. A glucagon suppression def...

J. J. Meier, C. F. Deacon, W. E. Schmidt, J. J. Holst, M. A. Nauck in Diabetologia (2007)

Article

Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans

Type 1 and type 2 diabetes are characterised by a beta cell deficit. Islet hyperplasia has been described in patients with Zollinger–Ellison syndrome secondary to gastrin-producing tumours (gastrinomas), and g...

J. J. Meier, A. E. Butler, R. Galasso, R. A. Rizza, P. C. Butler in Diabetologia (2006)

Article

Response to comment on: Meier JJ, Lin JC, Butler AE, Galasso R, Martinez DS, Butler PC (2006) Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia 49:1838–1844

J. J. Meier, J. C. Lin, A. E. Butler, R. Galasso, D. S. Martinez… in Diabetologia (2006)

Article

Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes

We investigated whether there was evidence of attempted beta cell regeneration in the pancreas obtained from a patient with recent-onset type 1 diabetes, and if so by what mechanism this occurred.

J. J. Meier, J. C. Lin, A. E. Butler, R. Galasso, D. S. Martinez… in Diabetologia (2006)

Article

Comment to: Patti ME, Mcmahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240

J. J. Meier, M. A. Nauck, P. C. Butler in Diabetologia (2006)

Article

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Diabetic dyslipidaemia contributes to the excess morbidity and mortality in patients with type 2 diabetes. Exogenous glucagon-like peptide 1 (GLP-1) lowers postprandial glycaemia predominantly by slowing gastr...

J. J. Meier, A. Gethmann, O. Götze, B. Gallwitz, J. J. Holst, W. E. Schmidt… in Diabetologia (2006)

Article

Increased vulnerability of newly forming beta cells to cytokine-induced cell death

Beta cell destruction in type 1 diabetes is apparently mediated by the release of cytokines. We questioned whether cytokine-induced apoptosis preferentially kills replicating beta cells.

J. J. Meier, R. A. Ritzel, K. Maedler, T. Gurlo, P. C. Butler in Diabetologia (2006)

Article

Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?

Type 1 diabetes is widely held to result from an irreversible loss of insulin-secreting beta cells. However, insulin secretion is detectable in some people with long-standing type 1 diabetes, indicating either...

J. J. Meier, A. Bhushan, A. E. Butler, R. A. Rizza, P. C. Butler in Diabetologia (2005)

Article

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes

The insulinotropic effect of gastric inhibitory polypeptide (GIP) is reduced in patients with type 2 diabetes and around 50% of their first-degree relatives under hyperglycaemic conditions. It is unknown wheth...

J. J. Meier, B. Gallwitz, M. Askenas, K. Vollmer, C. F. Deacon, J. J. Holst… in Diabetologia (2005)

Article

40^th EASD Annual Meeting of the European Association for the Study of Diabetes

M. Veitenhansl, K. Stegner, F.-X. Hierl, C. Dieterle, H. Feldmeier, B. Gutt… in Diabetologia (2004)